Cost-effectiveness of somatostatin analogues in the treatment of acromegaly

References

• Pivonello R, Auriemma RS, Grasso LF, et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary. 2017;20(1):46–62.
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243–248.
   PubMed Web of Science ®Google Scholar
• Katznelson L, Jr LER, Melmed S, et al. Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–3951.
   PubMed Web of Science ®Google Scholar
• Bolanowski M, Ruchala M, Zgliczynski W, et al. Acromegaly – a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports. Endokrynol Pol. 2014;65:326–331.
   PubMed Web of Science ®Google Scholar
• Samson SL. Pasireotide in acromegaly: an overview of current mechanistic and clinical data. Neuroendocrinology. 2015;102:8–17.
   PubMed Web of Science ®Google Scholar
• Placzek H, Xu Y, Mu Y, et al. Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis. J Manag Care Spec Pharm. 2015;21(12):1106–1112.
   PubMed Web of Science ®Google Scholar
• Broder MS, Neary MP, Chang E, et al. Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary. 2014;17(4):333–341.
   PubMed Web of Science ®Google Scholar
• Roset M, Merino-Montero S, Luque-Ramírez M, et al. Cost of clinical management of acromegaly in Spain. Clin Drug Investig. 2012;32(4):235–245.
   PubMed Web of Science ®Google Scholar
• Trevor AH, Willis D, Walker G, et al. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol. 2013;6:689–699.
   Google Scholar
• Schoefl C, Holger F, Grussendorf M, et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly register. Eur J Endocrinol. 2013;168:39–47.
   PubMed Web of Science ®Google Scholar
• Orlewska E, Kos-Kudla B, Sowinski J, et al. Dosage and costs of lanreotide Autogel 120 mg administered as part of routine acromegaly care in Poland - two years of data from Lanro-Study. Endokrynol Pol. 2015;66(2):142–148.
   PubMed Web of Science ®Google Scholar
• Sesmilo G. [Epidemiology of acromegaly in Spain]. Endocrinol Nutr. 2013;60(8):470–474.
   PubMedGoogle Scholar
• Didoni G, Grottol S, Gasco V, et al. Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest. 2004;27:1034–1039.
   PubMed Web of Science ®Google Scholar
• Moore D, Meads C, Roberts L, et al. The effectiveness and cost-effectiveness of somatostatin analogues in the treatment of acromegaly. Birmingham: West Midlands Health Technology Assessment Collaboration (WMHTAC); 2002. DPHE Report No. 37. 200.
   Google Scholar
• Valentim J, Passos V, Mataveli F, et al. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol. 2008;52(9):1452–1460.
   PubMedGoogle Scholar
• Moore DJ, Adi Y, Connock MJ, et al. Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord. 2009;8(9):20.
   Web of Science ®Google Scholar
• Biermasz NR, Roelfsema F, Pereira AM, et al. Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly. Expert Rev Pharmacoecon Outcomes Res. 2009;9(3):223–234.
   PubMedGoogle Scholar
• Marty R, Roze S, Kurth H. Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK. Med Devices (Auckl). 2012;5:39–44.
   PubMedGoogle Scholar
• Marko NF, LaSota E, Hamrahian AH, et al. Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly. J Neurosurg. 2012;117(3):522–538.
   PubMed Web of Science ®Google Scholar
• Duan L, Huang M, Yan H, et al. Cost-effectiveness analysis of two therapeutic schemes in the treatment of acromegaly: a retrospective study of 168 cases. J Endocrinol Invest. 2015;38(7):717–723.
   PubMed Web of Science ®Google Scholar
• Kimmell KT, Weil RJ, Marko NF. Multi-modal management of acromegaly: a value perspective. Pituitary. 2015;18(5):658–665.
   PubMed Web of Science ®Google Scholar
• Margusino-Framiñán L, Pertega-Diaz S, Pena-Bello L, et al. Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome. Eur J Intern Med. 2015;26(9):736–741.
   PubMed Web of Science ®Google Scholar
• Xuan JW, Zhang ZY, Wang YF, et al. [Cost-effectiveness analysis of octreotide long acting release and lanreotide slow release for the treatment of postoperative patients with active acromegaly in China]. Zhonghua Yi Xue Za Zhi. 2017;97(10):765–769.
   PubMedGoogle Scholar
• Salinas EG, Idrovo J, Rivas R, et al. Economic evaluation of long term somatostatin analogs in the treatment of acromegaly in Mexico: monotherapy vs sequential therapy. Value in Health. 2009;12(3):A100.
   Web of Science ®Google Scholar
• Salinas Escudero G, Idrovo J, Rivas R, et al. Economic evaluation of long term somatostatin analogs in the treatment of acromegaly in Mexico. Value in Health. 2009;11(3):A227.
   Web of Science ®Google Scholar
• Roze S, Kurth H. Maury le Breton A. Injection of Long-Acting Somatostatin Analogs: a Cost Consequence Analysis in France, Germany, the United Kingdom and the United States. Value Health. 2011;14(3):A164.
   Web of Science ®Google Scholar
• Alfonso R, Izquierdo C, Diaz-Sotelo OD, et al. Cost-effectiveness of somatostatin analogues for the treatment of acromegaly in Colombia. Value in Health. 2010;13(3):A59.
   Web of Science ®Google Scholar
• Fujii RK, Mould JF, Fernandes RA, et al. Economic evaluation of pegvisomant for active acromegaly patients who failed available therapies in Brazil – public health care system perspective. Value Health. 2012;15(4):A105.
   Web of Science ®Google Scholar
• Id B, Fja P, Brulais S, et al. Characteristics of long-acting somatostatin (SSA) use in acromegaly in the Netherlands. Value in Health. 2012;15(7):A506.
   Web of Science ®Google Scholar
• Kousoulakou H, Panayiotou-Pazaitou K, Pantazi E, et al. Economic evaluation of lanreotide autogel in the management of acromegaly in Greece. Value Health. 2014;17(7):A348–9.
   PubMed Web of Science ®Google Scholar
• He JJ, Hu SL, Li YM, et al. Pharmacoeconomic evaluation study on preoperative treatment of acromegaly with somatostatin analogues in Shanghai. Value Health. 2014;17(7):A745.
   PubMed Web of Science ®Google Scholar
• Ferreira CN, Rufino C, Santana CF. Acromegaly patients with inadequate response to maximum dose Octreotide-Lar who progress to treatment with pegvisomant: economic evaluation and incremental budget impact analysis from the public perspective to São Paulo State. Value Health. 2015;18(7):A842.
   PubMed Web of Science ®Google Scholar
• Hahl J, Kurki S, Miettinen T, et al. Cost-effectiveness of pasireotide long-acting in a treatment of acromegaly in Finland. Economic Evaluation Based on Finnish Auria Biobank Data on Health Care Resource Utilization. Value Health. 2015;18(7):A609.
   PubMed Web of Science ®Google Scholar
• Carlqvist P, Wilen-Koort A, Cost-Effectiveness A. Analysis of pasireotide long-acting compared to continued use of a first-line somatostatin antagonist for the treatment of acromegaly in Sweden. Value Health. 2016;19(7):A591.
   Web of Science ®Google Scholar
• Peral C, Cordido F, Gimeno V. Cost-effectiveness analysis of second-line pharmacological treatments of acromegaly in Spain. Value Health. 2017;20(9):A5578.
   Web of Science ®Google Scholar
• Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf). 2000;53(5):577–586.
   PubMed Web of Science ®Google Scholar
• Freda PU, Katznelson L, Lely AT, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90(8):4465–4473.
   PubMed Web of Science ®Google Scholar
• Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93(8):2957–2968.
   PubMed Web of Science ®Google Scholar
• Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S, et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. Luque RM, ed. PLoS ONE. 2013;8(4):e61523.
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Pivonello R, et al. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary. 2016;19:235–247.
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Bronstein MD, et al. Acromegaly consensus group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141–3148.
   PubMed Web of Science ®Google Scholar
• Leonart LP, Ferreira VL, Tonin FS, et al. Medical treatments for acromegaly: a systematic review and network meta-analysis. 2018 [cited 2018 Feb 8]. Value in Health.
   Google Scholar
• Störmann S, Schopohl J. Perspectives on investigational drugs for acromegaly. Expert Opin Investig Drugs. 2016;25(4):381–384.
   PubMed Web of Science ®Google Scholar
• Biermasz NR. New medical therapies on the horizon: oral octreotide. Pituitary. 2017;20(1):149–153.
   PubMed Web of Science ®Google Scholar
• Puig Domingo M. Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol (Oxf). 2015;83(1):3–14.
   PubMed Web of Science ®Google Scholar